×
ProPhase Labs Total Liabilities 2010-2024 | PRPH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ProPhase Labs total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
ProPhase Labs Total Liabilities 2010-2024 | PRPH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ProPhase Labs total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.6B
Takeda Pharmaceutical (TAK)
$44.1B
Merck (MKKGY)
$21.2B
Astellas Pharma (ALPMY)
$20.4B
Sandoz Group AG (SDZNY)
$19.7B
United Therapeutics (UTHR)
$18B
Summit Therapeutics (SMMT)
$15.6B
Neurocrine Biosciences (NBIX)
$12.6B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Jazz Pharmaceuticals (JAZZ)
$7.4B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.1B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.8B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B